Loading
CR-002 is an experimental antibody-drug conjugate from Crescent Biopharma, in phase 1 trials for non-small cell lung cancer, head and neck squamous cell carcinoma and advanced solid tumours.
CR-002 is an antibody-drug conjugate (topoisomerase inhibitor payload) from Crescent Biopharma. An antibody-drug conjugate that uses a highly internalising PD-L1 antibody to carry a topoisomerase inhibitor payload into tumour cells, with a linker designed to be cleaved inside the cell. Its furthest stage is phase 1, for non-small cell lung cancer, head and neck squamous cell carcinoma and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. FDA cleared the IND; the APOLLO phase 1/2 trial (NCT07909031) is listed as recruiting. Whether it works in people has not been established unless a trial below reports it.
An antibody-drug conjugate that uses a highly internalising PD-L1 antibody to carry a topoisomerase inhibitor payload into tumour cells, with a linker designed to be cleaved inside the cell. Connects to PD-L1.
1.CR-002's antibody arm binds PD-L1 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CR-002" OR ABSTRACT:"CR-002") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CR-002, not a curated reading list.
Shares Crescent Biopharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Crescent Biopharma, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/